International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients
- 1 May 2017
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 101 (5), 956-967
- https://doi.org/10.1097/tp.0000000000001704
Abstract
No abstract availableThis publication has 66 references indexed in Scilit:
- Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantationLiver Transplantation, 2012
- Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfectionLiver Transplantation, 2012
- Fibrosing Cholestatic Hepatitis in HIV/HCV Co-Infected Transplant Patients—Usefulness of Early Markers After Liver TransplantationAmerican Journal of Transplantation, 2011
- Clinical characterization of patients developing histologically‐proven fibrosing cholestatic hepatitis C post‐liver transplantationHepatology Research, 2011
- PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virusLiver Transplantation, 2011
- HBV and HIV Coinfection and Liver TransplantAmerican Journal of Transplantation, 2010
- Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled StudyGastroenterology, 2007
- Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosisLiver International, 2005
- Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C-Infected Patients Undergoing Liver TransplantationAmerican Journal of Transplantation, 2005
- Validation and refinement of survival models for liver retransplantationJournal of Hepatology, 2003